FAB Pharma, A Biopharma Company Developing Drugs To Treat Severe Bacterial Infections

Medical News Today reports that, FAB Pharma has acquired assets in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) from Mutabilis S.A. Severe infections caused by MRSA is a growing issue, especially in the hospital where it is one of the main causes of nosocomial infections. By definition, MRSA is resistant to a broad group of antibiotics. FAB Pharma's approach consists in developing a new class of low-molecular-weight antibacterial molecules which target a specific, essential enzyme in MRSA called Fatty Acid Biosynthesis I (FAB I).

There is a growing medical need for anti-MRSA drugs. Nosocomial infections constitute a major health problem, with 4 million cases reported each year in Europe and 2 million a year in the USA.

Will the anti-MSRA drug that FAB Pharma is developing work to help this millions of infected persons? Are there other companies working on a similar drug?


FAB Pharma, A Biopharma Company Developing Drugs To Treat Severe Bacterial Infections

Share this article with your social network, just click below to share now!

Share |

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

Reuters reports that those who suffer from Psoriasis may soon have relief. Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today that its 75-patient Phase II clinical study with CF101 to treat patients with moderate to severe Psoriasis has successfully met its primary objectives.

Patients in this double-blind study were randomly assigned to 1, 2 or 4 mg of
CF101 or placebo twice daily. The drug was taken orally as a monotherapy for 12
weeks.

Dr. Michael David, Head of the Department of Dermatology, Rabin Medical Center,
the study principal investigator said: "The study data is impressive and
promising. CF101 is a unique small molecule orally bioavailable drug with an
impressive safety profile based on accumulated experience in more than 700
patients. There is a market need in Psoriasis for small molecule drugs and I am
confident that Can Fite should progress with the clinical development of CF101
based on the study data."

For more information, please visit the original article.

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

Share this article with your social network, just click below to share now!

Share |